Melissa A Sanchez1, Susan Scheer2, Sue Shallow3, Sharon Pipkin2, Sandra Huang3. 1. San Francisco Department of Public Health, Communicable Disease Control and Prevention Section, Chronic Hepatitis Surveillance, San Francisco, CA. 2. San Francisco Department of Public Health, HIV Epidemiology Section, San Francisco, CA. 3. San Francisco Department of Public Health, Communicable Disease Control and Prevention Section, San Francisco, CA.
Abstract
OBJECTIVES: To describe the epidemiology of people coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV) and HIV in San Francisco, the San Francisco Department of Public Health's Communicable Disease Control and Prevention Section and the HIV Epidemiology Section collaborated to link their registries. METHODS: In San Francisco, hepatitis reporting is primarily through passive laboratory-based surveillance, and HIV/AIDS reporting is primarily through laboratory-initiated active surveillance. We conducted the registry linkage in 2010 using a sequential algorithm. RESULTS: The registry match included 31,997 HBV-infected people who were reported starting in 1984; 10,121 HCV-infected people who were reported starting in 2001; and 34,551 HIV/AIDS cases reported beginning in 1981. Of the HBV and HCV cases, 6.3% and 12.6% were coinfected with HIV, respectively. The majority of cases were white males; however, black people were disproportionately affected. For more than 90% of the HBV/HIV cases, male-to-male sexual contact (men who have sex with men [MSM]) was the risk factor for HIV infection. Injection drug use was the most frequent risk factor for HIV infection among the HCV/HIV cases; however, 35.6% of the HCV/HIV coinfected males were MSM but not injection drug users. CONCLUSIONS: By linking the two registries, we found new ways to foster collaborative work and expand our programmatic flexibility. This analysis identified particular populations at risk for coinfection, which can be used by viral hepatitis and HIV screening, prevention, and treatment programs to integrate, enhance, target, and prioritize prevention services and clinical care within the community to maximize health outcomes.
OBJECTIVES: To describe the epidemiology of people coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV) and HIV in San Francisco, the San Francisco Department of Public Health's Communicable Disease Control and Prevention Section and the HIV Epidemiology Section collaborated to link their registries. METHODS: In San Francisco, hepatitis reporting is primarily through passive laboratory-based surveillance, and HIV/AIDS reporting is primarily through laboratory-initiated active surveillance. We conducted the registry linkage in 2010 using a sequential algorithm. RESULTS: The registry match included 31,997 HBV-infectedpeople who were reported starting in 1984; 10,121 HCV-infectedpeople who were reported starting in 2001; and 34,551 HIV/AIDS cases reported beginning in 1981. Of the HBV and HCV cases, 6.3% and 12.6% were coinfected with HIV, respectively. The majority of cases were white males; however, black people were disproportionately affected. For more than 90% of the HBV/HIV cases, male-to-male sexual contact (men who have sex with men [MSM]) was the risk factor for HIV infection. Injection drug use was the most frequent risk factor for HIV infection among the HCV/HIV cases; however, 35.6% of the HCV/HIV coinfected males were MSM but not injection drug users. CONCLUSIONS: By linking the two registries, we found new ways to foster collaborative work and expand our programmatic flexibility. This analysis identified particular populations at risk for coinfection, which can be used by viral hepatitis and HIV screening, prevention, and treatment programs to integrate, enhance, target, and prioritize prevention services and clinical care within the community to maximize health outcomes.
Authors: Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward Journal: MMWR Recomm Rep Date: 2008-09-19
Authors: Deborah Konopnicki; Amanda Mocroft; S de Wit; Francisco Antunes; Bruno Ledergerber; Christine Katlama; K Zilmer; Stefano Vella; Ole Kirk; Jens D Lundgren Journal: AIDS Date: 2005-03-24 Impact factor: 4.177
Authors: Hannelore M Götz; Gerard van Doornum; Hubert Gm Niesters; Jan G den Hollander; H Bing Thio; Onno de Zwart Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: Thijs J W van de Laar; William A Paxton; Fokla Zorgdrager; Marion Cornelissen; Henry J C de Vries Journal: Sex Transm Dis Date: 2011-02 Impact factor: 2.830
Authors: Bernardino Roca; Ignacio Suarez; Juan Gonzalez; Myriam Garrido; Belen de la Fuente; Ramon Teira; Paloma Geijo; Jaime Cosin; Salvador Perez-Cortes; Maria Jose Galindo; Fernando Lozano; Pere Domingo; Pompeyo Viciana; Esteban Ribera; Antonio Vergara; Trinitario Sánchez Journal: J Infect Date: 2003-08 Impact factor: 6.072
Authors: Thijis van de Laar; Oliver Pybus; Sylvia Bruisten; David Brown; Mark Nelson; Sanjay Bhagani; Martin Vogel; Alex Baumgarten; Marie-Laure Chaix; Martin Fisher; Hannelore Gotz; Gail V Matthews; Stefan Neifer; Peter White; William Rawlinson; Stanislav Pol; Jurgen Rockstroh; Roel Coutinho; Greg J Dore; Geoffrey M Dusheiko; M Danta Journal: Gastroenterology Date: 2009-05 Impact factor: 22.682
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: K A Bosh; J R Coyle; V Hansen; E M Kim; S Speers; M Comer; L M Maddox; S Khuwaja; W Zhou; A Jatta; R Mayer; A D Brantley; N W Muriithi; R Bhattacharjee; C Flynn; L Bouton; B John; J Keusch; C A Barber; K Sweet; C Ramaswamy; E F Westheimer; L VanderBusch; A Nishimura; A Vu; L Hoffman-Arriaga; E Rowlinson; A O Carter; L E Yerkes; W Li; J R Reuer; L J Stockman; T Tang; J T Brooks; E H Teshale; H I Hall Journal: Epidemiol Infect Date: 2018-04-11 Impact factor: 2.451
Authors: Geoffrey McKee; Zahid A Butt; Stanley Wong; Travis Salway; Mark Gilbert; Jason Wong; Maria Alvarez; Nuria Chapinal; Maryam Darvishian; Mark W Tyndall; Mel Krajden; Naveed Z Janjua Journal: EClinicalMedicine Date: 2018-11-05
Authors: C Prussing; C Chan; J Pinchoff; L Kersanske; K Bornschlegel; S Balter; A Drobnik; J Fuld Journal: Epidemiol Infect Date: 2014-08-29 Impact factor: 4.434
Authors: Miranda S Moore; Angelica Bocour; Olivia C Tran; Baozhen Qiao; Maria J Schymura; Fabienne Laraque; Ann Winters Journal: Open Forum Infect Dis Date: 2018-06-16 Impact factor: 3.835